The estimated Net Worth of Edward J Rapp is at least $2.86 Million dollars as of 26 June 2019. Mr. Rapp owns over 7,500 units of AbbVie stock worth over $2,506,619 and over the last 12 years he sold ABBV stock worth over $0. In addition, he makes $348,864 as Independent Director at AbbVie.
Mr. Rapp ABBV stock SEC Form 4 insider trading
Edward has made over 21 trades of the AbbVie stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of ABBV stock worth $504,750 on 26 June 2019.
The largest trade he’s ever made was exercising 60,000 units of AbbVie stock on 31 January 2014 worth over $2,317,800. On average, Edward trades about 3,294 units every 43 days since 2008. As of 26 June 2019 he still owns at least 30,662 units of AbbVie stock.
You can see the complete history of Mr. Rapp stock trades at the bottom of the page.
Edward Rapp biography
Edward J. Rapp is an Independent Director of the Company. Mr. Rapp served as the Caterpillar Inc. group president for resource industries from 2014 until his retirement in mid-2016. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007. Mr. Rapp is presently a board member for FM Global. He is currently a member of the University of Missouri College of Business Strategic Development Board.
What is the salary of Edward Rapp?
As the Independent Director of AbbVie, the total compensation of Edward Rapp at AbbVie is $348,864. There are 9 executives at AbbVie getting paid more, with Richard Gonzalez having the highest compensation of $21,271,900.
How old is Edward Rapp?
Edward Rapp is 61, he’s been the Independent Director of AbbVie since 2013. There are 7 older and 12 younger executives at AbbVie. The oldest executive at AbbVie, Inc. is Edward Liddy, 73, who is the Independent Director.
What’s Edward Rapp’s mailing address?
Edward’s mailing address filed with the SEC is 1 N. WAUKEGAN ROAD, , NORTH CHICAGO, IL, 60064.
Insider trading at AbbVie
Over the last 7 years, insiders at AbbVie have traded over $114,130,047 worth of AbbVie stock and bought 207,390 units worth $13,938,118 . The most active insider traders include Richard A Gonzalez, Frederick H Waddell, and Glenn F Tilton. On average, AbbVie executives and independent directors trade stock every 21 days with the average trade being worth of $2,604,067. The most recent stock trade was executed by Timothy J. Richmond on 27 September 2019, trading 15,515 units of ABBV stock currently worth $1,163,935.
What does AbbVie do?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson’s disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
What does AbbVie’s logo look like?
Complete history of Mr. Rapp stock trades at AbbVie and Caterpillar
AbbVie executives and stock owners
AbbVie executives and other stock owners filed with the SEC include:
- Richard Gonzalez, Chairman of the Board, Chief Executive Officer
- Laura Schumacher, Vice Chairman, External Affairs and Chief Legal Officer
- Carlos Alban, Vice Chairman, Chief Commercial Officer
- William Chase, Executive Vice President – Finance and Administration
- Michael Severino, President, Vice Chairman
- Timothy Richmond, Chief Human Resource Officer, Executive Vice President
- Robert Michael, Chief Financial Officer, Senior Vice President
- Glenn Tilton, Lead Independent Director
- Robert Alpern, Independent Director
- Edward Rapp, Independent Director
- Frederick Waddell, Independent Director
- Melody Meyer, Independent Director
- William Burnside, Independent Director
- Roxanne Austin, Independent Director
- Brett Hart, Independent Director
- Edward Liddy, Independent Director
- Rebecca Roberts, Independent Director
- Brian Durkin, Vice President, Controller
- Jeffrey Stewart, Senior Vice President, U.S. Commercial Operations
- Nicholas Donoghoe, Senior Vice President – Enterprise Innovation
- Azita Saleki-Gerhardt, Executive Vice President – Operations
- Henry Gosebruch, Executive Vice President, Chief Strategy Officer
- Thomas A. Hurwich, VP, Controller
- Roy S Roberts, Director
- Laboratories Abbott, 10% owner
- John M. Leonard, SVP, Chief Scientific Officer
